Breaking News Instant updates and real-time market news.

CAMP

CalAmp

$10.41

0.25 (2.46%)

, PRGS

Progress Software

$40.64

0.79 (1.98%)

18:40
06/27/19
06/27
18:40
06/27/19
18:40

Fly Intel: After Hours Movers

UP AFTER EARNINGS: CalAmp (CAMP), up 24.7%... Progress Software (PRGS), up 17.7%... Avid Bioservices (CDMO), up 10.5%. ALSO HIGHER: Arcturus (ARCT), up 0.7% after it received FDA orphan drug designation for its OC deficiency treatment... BNY Mellon (BK), Goldman Sachs (GS), Bank of America (BAC) and JPMorgan (JPM), all higher after the Fed approved capital plans of all 18 banks. DOWN AFTER EARNINGS: Smart Global (SGH), down 14.1%. ALSO LOWER: Hutchison China MediTech (HCM), down 10.7% after it filed to sell 8.5M ADSs for holders.

CAMP

CalAmp

$10.41

0.25 (2.46%)

PRGS

Progress Software

$40.64

0.79 (1.98%)

CDMO

Avid Bioservices

$3.99

0.19 (5.00%)

ARCT

Arcturus Therapeutics

$9.58

-0.13 (-1.34%)

BK

BNY Mellon

$43.38

0.27 (0.63%)

GS

Goldman Sachs

$199.27

2.24 (1.14%)

BAC

Bank of America

$28.21

0.29 (1.04%)

JPM

JPMorgan

$108.81

0.33 (0.30%)

SGH

Smart Global

$21.43

0.52 (2.49%)

HCM

Hutchison China MediTech

$30.21

1.2 (4.14%)

  • 27

    Jun

  • 27

    Jun

  • 27

    Jun

  • 27

    Jun

  • 09

    Jul

  • 09

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 17

    Jul

  • 17

    Jul

  • 24

    Jul

  • 06

    Aug

  • 09

    Sep

  • 28

    Jun

CAMP CalAmp
$10.41

0.25 (2.46%)

03/25/19
03/25/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Akamai (AKAM) downgraded to Sell from Hold at Deutsche Bank with analyst Vijay Bhagavath saying his estimates for fiscal 2019 through fiscal 2021 are below consensus for both sales and earnings. 2. Nu Skin (NUS) downgraded to Sell from Hold at Stifel with analyst Mark Astrachan saying he sees increasing uncertainty surrounding direct selling companies in China relating to the investigation announced in January into the unlawful promotion and sale of health products. 3. TrueCar (TRUE) downgraded to Hold from Buy at Benchmark with analyst Daniel Kurnos saying he believes it may take several quarters for management to regain credibility, with each quarter heavily scrutinized along the way. 4. Texas Instruments (TXN) and Analog Devices (ADI) downgraded to Market Perform from Outperform at Bernstein. 5. CalAmp (CAMP) downgraded to Neutral from Overweight at JPMorgan with analyst Paul Coster saying he sees limited catalysts for the shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/09/19
FANA
04/09/19
NO CHANGE
FANA
Outperform
CalAmp should see better growth in 2019, says First Analysis
First Analysis analyst Howard Smith says his review of publicly traded telematics solutions providers suggests that despite a notable slowdown in organic growth in 2018, subscriber and revenue growth should rebound in 2019, helped by the second compliance deadline for the federal Electronic Logging Device mandate, the easing of recent headwinds, completion of strategic initiatives, and more favorable comps. CalAmp (CAMP) should see better growth in 2019 after a disappointing 2018, Smith tells investors in a research note. He keeps an Outperform rating on the shares. Further, the greater net subscriber additions MiX Telematics (MIXT) achieved in 2018, combined with subscriber base growth ahead of the public comp group, makes the analyst "incrementally more bullish" on the name. He has a Strong Buy rating on MiX.
05/29/19
GSCO
05/29/19
DOWNGRADE
Target $11
GSCO
Sell
CalAmp downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Jerry Revich downgraded CalAmp to Sell from Neutral and lowered his price target for the shares to $11 from $13. The analyst reduced his estimates for the company to reflect a cyclical slowdown in the truck and construction end-markets. Revich is positive on CalAmp's growing subscription business, but he believes that as the hardware business faces a cyclical slowdown, consensus EBITDA estimates have 12% downside. The analyst sees a "challenging" organic growth outlook for the company amid "rising signs of an end market slowdown off-peak."
03/25/19
JPMS
03/25/19
DOWNGRADE
Target $17
JPMS
Neutral
CalAmp downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Paul Coster downgraded CalAmp to Neutral from Overweight with an unchanged price target of $17. The analyst sees limited catalysts for the shares.
PRGS Progress Software
$40.64

0.79 (1.98%)

06/28/18
BNCH
06/28/18
UPGRADE
BNCH
Hold
Progress Software upgraded to Hold from Sell at Benchmark
Benchmark analyst Mark Schappel upgraded Progress Software to Hold citing valuation.
07/16/18
NATL
07/16/18
INITIATION
Target $50
NATL
Buy
Progress Software initiated with a Buy at National Securities
National Securities initiated Progress Software with a Buy and $50 price target.
06/28/18
06/28/18
UPGRADE

Hold
Progress Software upgraded to Hold after 22% pullback at Benchmark
As previously reported, Benchmark analyst Mark Schappel upgraded Progress Software to Hold from Sell following the stock's 22% pullback since early March when he had downgraded the shares. Despite recommending shareholders move to the sidelines, Schappel said his concerns about operating margins and cash flow still remain and he thinks the stock could trade down to the low $30s.
CDMO Avid Bioservices
$3.99

0.19 (5.00%)

05/09/19
JANY
05/09/19
DOWNGRADE
Target $5
JANY
Neutral
Avid Bioservices downgraded to Neutral from Buy at Janney Montgomery Scott
Janney Montgomery Scott analyst Paul Knight downgraded Avid Bioservices to Neutral from Buy citing the "surprise" resignation of CEO Roger Lias. The analyst halved his price target for the shares to $5 from $10.
09/11/18
HCWC
09/11/18
NO CHANGE
Target $11
HCWC
Buy
Avid Bioservices price target raised to $11 from $6 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Avid Bioservices to $11 saying the company's business development continues to ramp. The analyst reiterates a Buy rating on the shares following the Q1 results.
07/17/18
HCWC
07/17/18
NO CHANGE
Target $6
HCWC
Buy
Avid Bioservices price target raised to $6 from $5 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Avid Bioservices to $6 and keeps a Buy rating on the shares following the company's Q4 results. The analyst is encouraged by the continued growth in Avid's manufacturing backlog based on its efforts to grow the business.
ARCT Arcturus Therapeutics
$9.58

-0.13 (-1.34%)

04/05/19
HCWC
04/05/19
INITIATION
Target $15
HCWC
Buy
Arcturus Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce started Arcturus Therapeutics with a Buy rating and $15 price target. The company is well positioned to realize the potential of mRNA therapeutics, Arce tells investors in a research note. The analyst believes Arcturus may initiate the first ever trial of an mRNA therapeutic dosed chronically via IV injection and views its "broad" RNA platform as "highly competitive and differentiated."
02/19/19
02/19/19
INITIATION

Fly Intel: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Southern Copper (SCCO) initiated with a Buy at Goldman Sachs. 2. Arcturus Therapeutics (ARCT) initiated with a Buy at Laidlaw. 3. HEXO Corp (HEXO) initiated with an Outperform at Oppenheimer. 4. Group 1 Automotive (GPI) and Lithia Motors (LAD) were initiated with an Overweight at JPMorgan, while Penske Automotive (PAG) and Asbury Automotive (ABG) were initiated with a Neutral, and Sonic Automotive (SAH) and AutoNation (AN) were initiated with an Underweight at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/19/19
LDLW
02/19/19
INITIATION
Target $19
LDLW
Buy
Arcturus Therapeutics initiated with a Buy at Laidlaw
Laidlaw analyst Yale Jen started Arcturus Therapeutics with a Buy rating and $19 price target. With two clinical products advancing and the potential of collaborations generating more products, the company's Lunar LNP platform "could tackle one of the crucial processes in nucleic acid medicine," Jen tells investors in a research note.
09/20/18
09/20/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Ralph Lauren (RL) upgraded to Neutral from Underweight at Piper Jaffray with analyst Erinn Murphy, who remains concerned about the sustainability of Ralph Lauren's sales group, saying earnings estimates are likely to continue to grind higher given the company's "sound" cost control and favorable margin mix shift. 2. Caterpillar (CAT) upgraded to Outperform from Neutral at Baird with analyst Mig Dobre saying he believes demand growth should continue into 2019. 3. Copart (CPRT) upgraded to Buy from Hold at Gabelli with analyst Matthew Paige saying he raised his valuation multiple to 15x EBITDA from 12x to reflect the premium he believes the stock deserves relative to KAR Auction Service (KAR) given its EBITDA margin advantage and his view that current market conditions better support the salvage auction business than wholesale. 4. Arcturus Therapeutics (ARCT) upgraded to Strong Buy from Buy at WBB Securities. 5. First BanCorp (FBP) upgraded to Buy from Neutral at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BK BNY Mellon
$43.38

0.27 (0.63%)

06/18/19
DBAB
06/18/19
DOWNGRADE
Target $44
DBAB
Hold
BNY Mellon downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Brian Bedell downgraded Charles Schwab to Hold from Buy and lowered his price target for the shares to $44 from $50. The analyst is downgrading some interest rate sensitive stocks in the Brokers and Asset Managers space ahead of the Q2 reporting season.
04/18/19
RBCM
04/18/19
NO CHANGE
Target $52
RBCM
Sector Perform
BNY Mellon price target lowered to $52 from $58 at RBC Capital
RBC Capital analyst Gerard Cassidy lowered his price target on BNY Mellon to $52 and kept his Sector Perform rating, saying the company hit an "air pocket" in Q1 as revenues underperformed expectations due to pricing pressure and negative core business trends. The analyst notes that BNY Mellon is "focused on optimizing profitability through organic growth" but the stock may continued trading at the lower end of its historical multiple range until there is an improvement in pricing, a more benign outlook for interest rates, and more consistent positive operating leverage.
01/08/19
JEFF
01/08/19
DOWNGRADE
Target $91
JEFF
Hold
Jefferies cuts trust bank estimates, downgrades Northern Trust to Hold
Jefferies analyst Ken Usdin downgraded Northern Trust (NTRS) to Hold from Buy and lowered his price target for the shares to $91 from $121. The sharp Q4 decline in market levels weighs on trust banks' revenue estimates, Usdin tells investors in a research note. He downgraded Northern Trust with his 2020 earnings estimate now 7% below consensus. Trust bank valuations remain below historical averages, but slower organic growth and "less macro help" are challenges, says the analyst. He also lowered his price target for Hold-rated BNY Mellon (BK) to $50 and Hold-rated State Street (STT) to $70.
01/09/19
SBSH
01/09/19
DOWNGRADE
Target $52
SBSH
Neutral
BNY Mellon downgraded to Neutral from Buy at Citi
Citi analyst Keith Horowitz downgraded BNY Mellon to Neutral with a $52 price target. The analyst believes the company's valuation relative to peers has gotten full and says he cannot justify a strong case for 15% plus upside from current levels. He views BK as fairly valued at current prices.
GS Goldman Sachs
$199.27

2.24 (1.14%)

04/17/19
ODEN
04/17/19
UPGRADE
ODEN
Hold
Goldman Sachs upgraded to Hold from Sell at Odeon Capital
Odeon Capital analyst Dick Bove upgraded Goldman Sachs to Hold from Sell following details on the company's plan to "resurrect its fortunes." Bove said Goldman has the intellectual and financial capital to make it work, but it will take years to implement.
06/24/19
UBSW
06/24/19
NO CHANGE
UBSW
DFAST results encourgaing for Wells Fargo, says UBS
UBS analyst Saul Martinez said the DFAST results from the Federal Reserve, reported after the close on Friday, were most encouraging for "those who didn't fare as well last year," like Wells Fargo (WFC). He thinks Goldman Sachs (GS), Morgan Stanley (MS) and State Street (STT) look like they have room to reach his forecasted capital returns and also said lower stressed losses at Citi (C) and JPMorgan (JPM) could suggest that the current SCB proposal may not lead to materially higher minimum capital requirements, added Martinez. However, he thinks there could be some downside to his capital return estimates for Capital One (COF), which he notes have been above consensus.
06/20/19
ODEN
06/20/19
UPGRADE
ODEN
Buy
Goldman Sachs upgraded to Buy from Hold at Odeon Capital
Odeon Capital analyst Dick Bove upgraded Goldman Sachs to Buy from Hold.
06/20/19
06/20/19
UPGRADE

Buy
Odeon Capital says Goldman Sachs 'exciting again,' ups rating to Buy
As previously reported, Odeon Capital analyst Dick Bove upgraded Goldman Sachs to Buy from Hold saying that while the 2019 earnings estimates for the company had been falling consistently in the past 6 months, the projections are now starting to rise due to the bank's "strong" showing in investment banking and the impact that rising asset values may be having on the asset management business. Bove believes there is more to Goldman "than a strong second quarter," as it experiments with a series of new business thrusts. The company has the intellectual and financial capital to make many of these thrusts successful, he contends, adding that Goldman is "exciting again and it is becoming a compelling investment."
BAC Bank of America
$28.21

0.29 (1.04%)

06/14/19
RAJA
06/14/19
NO CHANGE
RAJA
State Street, BofA, PNC among likely CCAR 'winners,' says Raymond James
Ahead of the Fed's release of its annual Comprehensive Capital Analysis Review, or CCAR, on June 27, Raymond James analysts led by David Long previewed the event, noting that "less complex" firms with $100B-$250B in assets have been effectively removed from this year after the central bank moved them to a two-year stress test cycle. Of the 18 total bank holding companies reviewed, and the seven of which the firm covers, Long and the team see State Street (STT), Bank of America (BAC) and PNC Financial (PNC) as "likely winners," they noted.
06/17/19
BMOC
06/17/19
UPGRADE
BMOC
Outperform
Bank of America upgraded to Outperform from Market Perform at BMO Capital
06/17/19
BMOC
06/17/19
UPGRADE
Target $37
BMOC
Outperform
BMO upgrades Bank of America to Outperform, sees 34% return potential
BMO Capital analyst James Fotheringham upgraded Bank of America to Outperform from Market Perform with an unchanged price target of $37. The stock closed Monday down 11c to $27.93. The analyst expects upward consensus estimates revisions and a "multiple re-rating" to drive 34% total return in the shares. Bank of America's current valuation multiple is 15% below its long-term average, Fotheringham tells investors in a research note. Further, even if the Federal Reserve cuts rates, positive earnings revisions from better fees, tax rates, provisions and buybacks should "more than offset" any related net interest margin dilution, contends the analyst.
06/18/19
06/18/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bank of America (BAC) upgraded to Outperform from Market Perform at BMO Capital with analyst James Fotheringham expecting upward consensus estimates revisions and a "multiple re-rating" to drive 34% total return in the shares. 2. SunPower (SPWR), SunRun (RUN) upgraded to Buy from Neutral as SolarEdge (SEDG) upgraded to Neutral from Sell at Goldman Sachs with analyst Brian Lee anticipating "volume tailwinds" in the second half of 2019 given the recent signs of strength in the sector's financing environment. 3. CNH Industrial (CNHI) upgraded to Hold from Sell at Deutsche Bank with analyst Chad Dillard saying he's turning positive on North America large agriculture. 4. U.S. Cellular (USM), Telephone and Data (TDS) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Simon Flannery stating that he sees both stocks as "very attractively valued" with each down over 20% from their recent peak levels. 5. Prosperity Bancshares (PB) upgraded to Market Perform from Underperform at Raymond James with analyst Michael Rose saying the LegacyTexas Financial (LTXB) transaction provides meaningful scale in some of the most attractive markets in the country. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
JPM JPMorgan
$108.81

0.33 (0.30%)

06/19/19
MSCO
06/19/19
NO CHANGE
MSCO
Visa, MasterCard disruption threat from Libra 'fairly low,' says Morgan Stanley
After Facebook (FB) unveiled its cryptocurrency Libra yesterday, Morgan Stanley analysts led by Brian Nowak highlighted six "key questions" they still have about the impact on Facebook, commerce and the overall global banking and payments system from the social media giant's offering. The team, as previously stated, believe that Instagram commerce could be a greater than $4B annual opportunity for Facebook and even larger over the long term across Instagram, Messenger, WhatsApp and the core app. However, they also think costs may rise as they believe Facebook is likely going to have to fund rewards to drive Libra adoption. Libra's real-time aspect largely already exists in the banking system, except for in real-time cross-border payments, which is a challenge that Facebook could address, though it won't be alone there as JPMorgan (JPM) is also working on its own s Interbank Information Network blockchain, the team noted. The team believes Libra's threat of disruption to Visa (V) and Mastercard (MA) is "fairly low" as the major networks have a significant scale advantage, low costs, mature fraud detection abilities and they are both also founding members and investors, Nowak and the analysts also noted.
03/19/19
KEYB
03/19/19
DOWNGRADE
KEYB
Sector Weight
Worldpay downgraded to Sector Weight after Fiserv deal at KeyBanc
As previously reported, KeyBanc analyst Josh Beck downgraded Worldpay (WP) to Sector Weight from Overweight after the company and FIS (FIS) announced a deal, quickly adding another mega-deal in the wake of Fiserv (FISV)-First Data (FDC) and Global Payments (GPN)-Heartland Payment Systems. The analyst thinks this transaction is likely to expand the M&A discussion around Global Payments, TSYS (TSS), EVO Payments (EVOP), and i3 Verticals (IIIV) and sees paths to accretion should management teams further endorse a scale strategy. Future processing competition could increase among Global Payments, TSYS, First Data, and JPMorgan (JPM), but it remains too early to gauge, he contends.
03/25/19
JEFF
03/25/19
NO CHANGE
JEFF
Jefferies downgrades Financials to Underweight on 'shocking' Fed meeting
Jefferies analyst Steven DeSanctis is "very surprised" by last week's Federal Reserve's decision taking rate hikes completely off table in 2019. The "shocking" Fed meeting means lower rates for longer, which is not good for Financials, DeSanctis tells investors in a research note. A "lack of catalysts and weaker earnings growth" going forward for the entire sector, not just banks, means an Underweight rating on the space makes sense, says the analyst. As such, he downgraded his rating on the Financial sector to Underweight from Market Weight. Publicly traded companies in the space include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
SGH Smart Global
$21.43

0.52 (2.49%)

03/29/19
LEHM
03/29/19
NO CHANGE
Target $25
LEHM
Overweight
Smart Global price target lowered to $25 from $38 at Barclays
Barclays analyst Blayne Curtis lowered his price target for Smart Global Holdings to $25 from $38 after the company issued guidance "well below" expectations. Brazil customers are opting to wait until the second half to meet local content rules given the weakening pricing environment, Curtis tells investors in a research note. On the "brighter side," Penguin is on plan and Brazil should improve as customers fulfill the content requirements for the remainder of the year, says the analyst. He keeps am Overweight rating on Smart Global.
03/29/19
ROTH
03/29/19
NO CHANGE
Target $30
ROTH
Buy
Smart Global price target lowered to $30 from $40 at Roth Capital
Roth Capital analyst Suji Desilva lowered his price target on Smart Global shares to $30 from $40 after the company gave guidance well below consensus expectations, mainly due to diminished pricing and mix in the Brazil mobile segment. However, Desilva said he expects longer-term recovery in Brazil and believes Smart's growth opportunity in its non-Brazil segments remains intact. He maintains a Buy rating on the stock, which is down $4.39, or 18%, to $19.48 in pre-market trading.
03/29/19
DBAB
03/29/19
NO CHANGE
Target $28
DBAB
Buy
Smart Global price target lowered to $28 from $38 at Deutsche Bank
Deutsche Bank analyst Sidney Ho lowered his price target for Smart Global Holdings to $28 from $38 but keeps a Buy rating on the shares. The weak guidance was not unexpected and while there are more uncertainties, these are largely reflected in the share price, Ho tells investors in a post-earnings research note.
01/09/19
NEED
01/09/19
DOWNGRADE
NEED
Hold
Smart Global downgraded to Hold at Needham after Q1 earnings miss
As reported earlier, Needham analyst Rajvindra Gill downgraded Smart Global two notches to Hold from Strong Buy after the company's Q1 earnings and Q2 guidance yesterday. The analyst says he had expected unit growth driven by the rise in "local content rules to 60% in 2019", but with the company's largest smartphone customers pushed out memory purchases due to declining memory prices, local content rules are now expected to remain at 50% throughout 2019. Subsequently, Gill expects Brazil segment sales to decline 20-25% in FY19 and believes that a neutral stance on the stock is warranted by the "lack of mobile growth and a steep cut to estimates".
HCM Hutchison China MediTech
$30.21

1.2 (4.14%)

03/27/19
HSBC
03/27/19
INITIATION
HSBC
Buy
Hutchison China MediTech initiated with a Buy at HSBC
HSBC analyst Steve McGarry earlier today initiated coverage of Hutchison China MediTech with a Buy rating and 5,940 pence price target. The company's late stage oncology pipeline assets are "promising" and "could be transformative," McGarry told investors in a research note. Further, Hutchison has "significant" Pharma and Consumer Health businesses in China that generate sales and profits, adds the analyst.
03/04/19
DBAB
03/04/19
INITIATION
Target $35
DBAB
Buy
Hutchison China MediTech initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Richard Parkes started Hutchison China MediTech with a Buy rating and $35 price target. The analyst believes the shares offer "significant upside potential" as the company leverages its pipeline of cancer-focused drugs in both domestic and global markets.

TODAY'S FREE FLY STORIES

DDAIF

Daimler AG

$0.00

(0.00%)

18:46
07/15/19
07/15
18:46
07/15/19
18:46
Initiation
Daimler AG initiated  »

Daimler AG initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PUGOY

Peugeot

$0.00

(0.00%)

18:46
07/15/19
07/15
18:46
07/15/19
18:46
Initiation
Peugeot initiated  »

Peugeot initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$14.18

0.045 (0.32%)

18:45
07/15/19
07/15
18:45
07/15/19
18:45
Initiation
Fiat Chrysler initiated  »

Fiat Chrysler initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

TGI

Triumph Group

$23.07

-0.22 (-0.94%)

18:42
07/15/19
07/15
18:42
07/15/19
18:42
Hot Stocks
Triumph Group selected by leading airline as MRO provider »

Triumph Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 31

    Jul

TRQ

Turquoise Hill

$1.07

-0.02 (-1.83%)

18:32
07/15/19
07/15
18:32
07/15/19
18:32
Hot Stocks
Turquoise Hill reports Q2 copper output 39.2KT, down 0.6% from last year »

Reports Q2 Gold output…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIO

Rio Tinto

$61.50

0.77 (1.27%)

18:29
07/15/19
07/15
18:29
07/15/19
18:29
Hot Stocks
Rio Tinto cuts FY19 Pilbara ore shipments view to 320M-330M tons »

Prior view was 333M-343M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

RIO

Rio Tinto

$61.50

0.77 (1.27%)

18:28
07/15/19
07/15
18:28
07/15/19
18:28
Hot Stocks
Rio Tinto report Q2 Pilbara iron ore output 79.7M tons, down 7% from last year »

Reports Q2 Pilbara iron…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

VMW

VMware

$172.22

2.48 (1.46%)

18:24
07/15/19
07/15
18:24
07/15/19
18:24
Hot Stocks
VMware: We have momentum across the board »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

CGIX

Cancer Genetics

$0.17

-0.0059 (-3.35%)

, IDXG

Interpace Diagnostics

$0.70

-0.0071 (-1.01%)

18:21
07/15/19
07/15
18:21
07/15/19
18:21
Conference/Events
Interpace Diagnostics to hold a conference call »

Conference call to…

CGIX

Cancer Genetics

$0.17

-0.0059 (-3.35%)

IDXG

Interpace Diagnostics

$0.70

-0.0071 (-1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

17:55
07/15/19
07/15
17:55
07/15/19
17:55
Conference/Events
Stephens business services analyst to hold a group dinner »

Group Dinner Meeting to…

EYEN

Eyenovia

$2.89

0.04 (1.40%)

17:51
07/15/19
07/15
17:51
07/15/19
17:51
Hot Stocks
Eyenovia CEO buys 233.8K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ET

Energy Transfer LP

$14.91

0.09 (0.61%)

17:38
07/15/19
07/15
17:38
07/15/19
17:38
Periodicals
Energy Transfer considering sale of 33% Rover pipeline stake, Bloomberg says »

Energy Transfer (ET) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INNT

Innovate Biopharmaceuticals

$1.12

0.02 (1.82%)

17:37
07/15/19
07/15
17:37
07/15/19
17:37
Hot Stocks
Innovate Biopharmaceuticals gives corporate update, undertakes CEO search effort »

Innovate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LAMR

Lamar Advertising

$80.70

-0.31 (-0.38%)

17:36
07/15/19
07/15
17:36
07/15/19
17:36
Hot Stocks
Lamar Advertising to acquire Ashby Street Outdoor Holdings »

Ashby Street Outdoor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

LMT

Lockheed Martin

$367.65

-1.81 (-0.49%)

17:24
07/15/19
07/15
17:24
07/15/19
17:24
Hot Stocks
Lockheed Martin awarded $492.11M Army contract for M142 launchers »

Lockheed Martin was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

EGHT

8x8, Inc.

$25.62

-0.24 (-0.93%)

, FIVN

Five9

$48.00

-5.53 (-10.33%)

17:15
07/15/19
07/15
17:15
07/15/19
17:15
Conference/Events
Stephens communications analysts to hold an analyst/industry conference call »

Communications Analysts,…

EGHT

8x8, Inc.

$25.62

-0.24 (-0.93%)

FIVN

Five9

$48.00

-5.53 (-10.33%)

LOGM

LogMeln

$76.57

0.41 (0.54%)

RNG

RingCentral

$123.31

0.34 (0.28%)

WORK

Slack Technologies

$34.78

1.04 (3.08%)

TWLO

Twilio

$145.36

3.185 (2.24%)

VG

Vonage

$12.79

-0.2 (-1.54%)

ZM

Zoom Video

$99.76

6.465 (6.93%)

GOOG

Alphabet

$1,150.39

5.84 (0.51%)

MSFT

Microsoft

$138.94

0.08 (0.06%)

AMZN

Amazon.com

$2,021.00

10.38 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 01

    Aug

  • 06

    Aug

  • 08

    Aug

  • 08

    Aug

  • 27

    Oct

  • 13

    Nov

WTI

W&T Offshore

$4.83

0.13 (2.77%)

17:08
07/15/19
07/15
17:08
07/15/19
17:08
Hot Stocks
W&T Offshore CEO buys 100K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRT

StarTek

$7.10

0.04 (0.57%)

17:08
07/15/19
07/15
17:08
07/15/19
17:08
Syndicate
Breaking Syndicate news story on StarTek »

StarTek files $100M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

VTVT

vTv Therapeutics

$1.37

(0.00%)

17:08
07/15/19
07/15
17:08
07/15/19
17:08
Hot Stocks
vTv Therapeutics jumps 20% after saying it will make presentation at AAIC »

vTv Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JBHT

J.B. Hunt

$92.50

-0.45 (-0.48%)

16:53
07/15/19
07/15
16:53
07/15/19
16:53
Hot Stocks
Breaking Hot Stocks news story on J.B. Hunt »

J.B. Hunt up over 6% at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jul

  • 26

    Aug

  • 13

    Nov

ARW

Arrow Electronics

$68.82

-0.15 (-0.22%)

16:52
07/15/19
07/15
16:52
07/15/19
16:52
Hot Stocks
Breaking Hot Stocks news story on Arrow Electronics »

Arrow Electronics down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBNK

United Financial

$14.02

-0.1 (-0.71%)

16:45
07/15/19
07/15
16:45
07/15/19
16:45
Hot Stocks
Breaking Hot Stocks news story on United Financial »

United Financial trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

TRWH

Twin River Worldwide

$28.90

-0.08 (-0.28%)

16:44
07/15/19
07/15
16:44
07/15/19
16:44
Hot Stocks
Standard General to tender 13M shares from Twin River Worldwide »

Twin River Worldwide…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HQY

HealthEquity

$70.29

-1.38 (-1.93%)

16:44
07/15/19
07/15
16:44
07/15/19
16:44
Hot Stocks
HealthEquity director Robert Selander buys 610K in company shares »

HealthEquity director…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSS

TSYS

$133.45

1.26 (0.95%)

, GPN

Global Payments

$165.94

1.69 (1.03%)

16:39
07/15/19
07/15
16:39
07/15/19
16:39
Hot Stocks
Global Payments establishes new credit agreement to support merger with TSYS »

Global Payment (GPN)…

TSS

TSYS

$133.45

1.26 (0.95%)

GPN

Global Payments

$165.94

1.69 (1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.